My Treatment Approach: My Treatment Approach: Navigating Genetic Testing and RET-Targeted Treatments in NSCLC - Episode 5

Clinical-Decision Making: When to Treat Advanced NSCLC Without Mutational Results

,

Panelists discuss how to balance the need for comprehensive biomarker testing with the urgency to initiate treatment in patients with advanced disease and explore situations where treatment might be started before test results are available.

EP. 1: Patient Case: 67 Year-Old Male With Stage IIIB+ NSCLC Awaiting for Mutation Testing
EP. 2: Next Steps to Stage IIIB NSCLC Patient Case Awaiting Molecular Testing and Usability of Liquid Biopsy
EP. 3: Testing Methodologies and Standards in Metastatic NSCLC
EP. 4: Practical Considerations in Metastatic NSCLC: Access and Timing of Testing
Now Viewing
EP. 5: Clinical-Decision Making: When to Treat Advanced NSCLC Without Mutational Results
EP. 6: Initial Approach to Management of RET-Positive NSCLC
  1. Dr Wakelee: Please comment on balancing the need for comprehensive biomarker testing with the urgency to start treatment, especially in patients with advanced disease.
    1. In what types of situations would you initiate treatment prior to having test results?